Humatrope 72IU (24mg)*Lilly

$350.00

Humatrope 72IU (24mg)*Lilly

 

Humatrope 72IU(24mg)*Lilly

Humatrope 72IU; Important Things to Know It is important to learn the names of the parts of the Humatrope Cartridge Kit and how these parts work before injecting yourself or your child. Make sure you have been properly trained by your nurse, pharmacist or doctor before you mix the drug (add the diluent liquid to the dry Humatrope powder) or inject it. Wash your hands and be careful to follow the instructions given to you by your nurse, pharmacist or doctor. After mixing, throw away the diluent syringe in a puncture-resistant container such as the type your nurse, pharmacist or doctor has told you to use. Storage Humatrope must be kept refrigerated (36° to 46°F [2° to 8°C]) before and after it is mixed. Do not freeze. Once Humatrope has been mixed and is in liquid form, it must be used within 28 days. Throw away any mixed Humatrope left over after 28 days. Before giving an injection, check the date on the cartridge. Do not use the cartridge if it has expired. WARNING HUMATROPE CARTRIDGES SHOULD NOT BE USED IF THE PATIENT IS ALLERGIC TO METACRESOL OR GLYCERIN. Contents

Humatrope contains a growth hormone, a genetic engineering and a structure identical to that of human origin, secreted in the circulation by a gland in the brain (pituitary gland).

In case of hormonal growth, one tries, by daily subcutaneous injection before bedtime, to imitate the rate of release of the natural growth hormone.

children
Humatrope 72IU is used in the treatment of clinical dwarfism, linked to confirmed growth hormone deficiency, as well as in the treatment of dwarfism in pregnancy. young girls and women, with dwarfism and ovarian hypotrophy as main symptoms).

Humatrope is used in the nanism of prepubertal children with chronic renal failure.

 

Dosage :
Adult:
Give by SC inj once daily; rotate inj sites. Individualize. Weight-based: Initially up to 0.006mg/kg/day; may increase to max 0.0125mg/kg/day. Non-weight based: approx. 0.2mg/day (range: 0.15–0.3mg/day), may increase gradually every 1–2 months by increments of approx. 0.1–0.2mg/day.

Children:
Rotate inj sites. Weekly dose should be divided over 6 or 7 days of SC inj. GH deficient: 0.18 to 0.3mg/kg/week. Turner syndrome: up to 0.375mg/kg/week. ISS: up to 0.37mg/kg/week. SHOX deficiency: 0.35mg/kg/week. SGA: up to 0.47mg/kg/week.

Contraindications:
Acute critical illness due to surgical complications or multiple accidental trauma or those with acute respiratory failure. Closed epiphyses. Active malignancy or growing intracranial tumors. Diabetic retinopathy. History of upper airway obstruction or sleep apnea, severe obesity, or severe respiratory impairment in Prader-Willi syndrome (PWS) patients. Not indicated for treatment of children with growth failure due to confirmed PWS.

 

Side Effects :
Side effects of Humatrope 72IU ; Headache, nausea, vomiting, fatigue, muscle pain, or weakness may occur. If these symptoms continue or become bothersome, inform your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

warnings !

Before using any medication, be sure to tell your doctor about any medical conditions or allergies you may have, medications you are using, and other important things about your health. Women should mention if they are pregnant or breastfeeding. These factors could affect how you should use this medicine.

Cancer: For people who have survived Cancer in childhood, taking growth hormone can increase the risk of tumor growth, whether cancerous or not. Talk to your doctor about any concerns you may have about it.

Diabetes: Somatropin can increase blood sugar levels and change glucose tolerance. People with diabetes may need to check their blood sugar more often while taking this medication.

If you have diabetes or are predisposed to diabetes, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and the relevance of specific medical surveillance.

Hypothyroidism (a low level of thyroid hormones): In cases of rebel hypothyroidism, treatment with somatropin may be relatively successful. Discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Treatment with somatropin may trigger hypothyroidism. If you experience weight gain, muscle pain or stiffness, constipation, dry skin, or fatigue, it may be due to thyroid hormone deficiency. You should contact your doctor as soon as possible.

Scoliosis: People with scoliosis are at risk of worsening this condition while using somatropin. People with scoliosis should discuss with their doctor how this medication may affect their medical condition, how their medical condition may affect the dosing and effectiveness of this medication, and whether any medical attention is needed. specific.

Pregnancy: This medication should not be used during pregnancy unless the benefits outweigh the risks. If pregnancy occurs while you use this medicine, contact your doctor immediately.

Breast-feeding: It is not known if somatropin passes into breast milk. If you take this medicine while you are breastfeeding, your baby may feel the effects. Consult your doctor to find out if you should continue breastfeeding.

Seniors: The safety and effectiveness of this medication have not been established for adults over 65 years of age.

 

The somatropin concentrations for the reconstituted Humatrope cartridges are as follows:

06 mg cartridge (gold) 2.08 mg/mL
12 mg cartridge (teal) 4.17 mg/mL
24 mg cartridge (purple) 8.33 mg/mL

Reviews

There are no reviews yet.

Be the first to review “Humatrope 72IU (24mg)*Lilly”

Your email address will not be published. Required fields are marked *

You cannot copy content of this page